Dr. Kalimuthu Karuppanan obtained his Ph.D. in Biotechnology from Madurai Kamaraj University, India (2013). He was a postdoctoral scientist and Lecturer in Department of Chemical Engineering, University of California, Davis, USA (2014-2018). He relocated for his second postdoctoral scientist position in Radcliffe Department of Medicine, University of Oxford, UK (2019-2021). Also, he was a Co-Investigator in Center for the Utilization of Biological Engineering in Space (CUBES) project, NASA-Space technology Research Institutes, USA, and Co-Investigator in Emergency Response to the Novel Coronavirus Pandemic (COVID-19) project funded by KFAS-Kuwait University, Kuwait. He has contributed to various therapeutic protein engineering and developments (including Zmapp cocktail antibodies for Ebola and Fc fusion proteins for SARS-CoV-2 infection). He has one approved US patent, various prestigious drug discovery awards and peer-reviewed journal publications for his research accomplishment in Biotherapeutics.